Evidence map›Paper›PMID 40698148›Full record

ReviewActa pharmaceutica Sinica. B2025

Advances in research on biomaterials and stem cell/exosome-based strategies in the treatment of traumatic brain injury.

Wenya Chi, Yingying He, Shuisheng Chen, Lingyi Guo, Yan Yuan, Rongjie Li, Ruiyao Liu, Dairan Zhou, Jianzhong Du, Tao Xu and 1 more

Abstract readReview
In one paragraph

Review in Acta pharmaceutica Sinica. B, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. FTO-mediated mActa pharmaceutica Sinica. B · 2026
    Article
  5. Selenized neural stem cell exosomes for CNS trauma repair.Extracellular vesicles and circulating nucleic acids · 2026
    Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Wenya ChiDepartment of Pharmaceutical Science, Faculty of Pharmacy, Naval Medical University, Shanghai 200433, China.
Yingying HeDepartment of Pharmaceutical Science, Faculty of Pharmacy, Naval Medical University, Shanghai 200433, China.
Shuisheng ChenDepartment of Pharmaceutical Science, Faculty of Pharmacy, Naval Medical University, Shanghai 200433, China.
Lingyi GuoDepartment of Pharmaceutical Science, Faculty of Pharmacy, Naval Medical University, Shanghai 200433, China.
Yan YuanDepartment of Pharmaceutical Science, Faculty of Pharmacy, Naval Medical University, Shanghai 200433, China.
Rongjie LiDepartment of Pharmaceutical Science, Faculty of Pharmacy, Naval Medical University, Shanghai 200433, China.
Ruiyao LiuDepartment of Pharmaceutical Science, Faculty of Pharmacy, Naval Medical University, Shanghai 200433, China.
Dairan ZhouDepartment of Neurosurgery, Changzheng Hospital, Naval Medical University, Shanghai 200003, China.
Jianzhong DuDepartment of Gynaecology and Obstetrics, Shanghai Key Laboratory of Anesthesiology and Brain Functional Modulation, Clinical Research Center for Anesthesiology and Perioperative Medicine, Translational Research Institute of Brain and Brain-Like Intelligence, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai 200434, China.
Tao XuDepartment of Neurosurgery, Changzheng Hospital, Naval Medical University, Shanghai 200003, China.
Yuan YuDepartment of Pharmaceutical Science, Faculty of Pharmacy, Naval Medical University, Shanghai 200433, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Traumatic brain injury (TBI) is intricately linked to the most severe clinical manifestations of brain damage. It encompasses dynamic pathological mechanisms, including hemodynamic disorders, excitotoxic injury, oxidative stress, mitochondrial dysfunction, inflammation, and neuronal death. This review provides a comprehensive analysis and summary of biomaterial-based tissue engineering scaffolds and nano-drug delivery systems. As an example of functionalized biomaterials, nano-drug delivery systems alter the pharmacokinetic properties of drugs. They provide multiple targeting strategies relying on factors such as morphology and scale, magnetic fields, pH, photosensitivity, and enzymes to facilitate the transport of therapeutics across the blood-brain barrier and to promote selective accumulation at the injury site. Furthermore, therapeutic agents can be incorporated into bioscaffolds to interact with the biochemical and biophysical environment of the brain. Bioscaffolds can mimic the extracellular matrix environment, regulate cellular interactions, and increase the effectiveness of local treatments following surgical interventions. Additionally, stem cell-based and exosome-dominated extracellular vesicle carriers exhibit high bioreactivity and low immunogenicity and can be used to design therapeutic agents with high bioactivity. This review also examines the utilization of endogenous bioactive materials in the treatment of TBI.

Indexed as

BiomaterialBioscaffoldExosomeExtracellular matrixNano-drug delivery systemRegenerationStem cellTraumatic brain injury

Identifiers

PMID40698148
PMCPMC12278432

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.